Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Peking University Cancer Hospital, Beijing, Beijing Municipality, China
Hunan Cancer Hospital, Changsha, Hunan, China
The first hospital of Jilin University, Changchun, Jilin, China
West China Hospital, Chengdu, Sichuan, China
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Lishui Central Hospital, Lishui, Zhejiang, China
Zhongshan Hospital Fudan University, Shanghai, China
Contact: Study coordinator (Jian Zhou, MD)